The 11 analyst ratings for Avadel Pharmaceuticals in the last quarter are mostly bullish, with an average price target of $16.5, which is higher than the current price of $13.49. This indicates a potential upside for the stock in the short term. The average price target has also increased by 10.52% over the past month, showing growing optimism among analysts.